Risk factor
Very poor trading liquidity
Profitability factor
Very low or no dividends
About
ContextVision AB (publ), a medical technology enterprise established in Stockholm, Sweden, in 1983, delivers sophisticated software solutions. The firm specializes in image analysis and artificial intelligence, supplying these advanced technologies to original equipment manufacturers (OEMs) across Asia, Europe, and the United States. Their comprehensive product suite is designed to optimize image quality across various medical imaging modalities, including two-dimensional, three-dimensional, and four-dimensional ultrasound, radiography, magnetic resonance imaging (MRI), and mammography. Key offerings include: Rivent: Provides superior image quality for a broad spectrum of ultrasound applications such as women's health, general imaging, cardiovascular, and point-of-care. VolarView: An image enhancement software specifically developed for the burgeoning handheld ultrasound market. GOPiCE: A proprietary technology enabling real-time volumetric image enhancement. Altumira/Altumira Plus: A robust platform for digital radiography. An Orthopedic Package: Tailored for specialized orthopedic imaging needs. GOPView MRI2Plus: An advanced solution for MRI image improvement. INIFY Prostate Screening: Offers digital analysis for prostate biopsies.
Company Valuation
Considering past and projected metrics, the stock is neither 'expensive' nor 'cheap' compared to its peers. Specifically, the stock is fairly valued on P/E, neutral on EV
Target Price
The average target price of CONTX.OL is 3.30 and suggests 19.9% downside potential. Usually, this means a SELL recommendation among investment firms, or a recommendation